Panoramic view of Celltrion headquarters. Provided by Celltrion
Celltrion announced on the 4th that it had disclosed preclinical study results for its new obesity treatment candidate “CT-G32/SCO-940,” which simultaneously targets four hormone pathways. The company stated that animal studies comparing it with existing triple agonists confirmed a greater weight loss effect and the potential to preserve lean body mass.
According to Celltrion, the study results were jointly presented with Japan’s Scohia Pharma at the global specialist conference “TIDES Europe,” held in Amsterdam, the Netherlands, from the 3rd to the 5th (local time). The research included cell activity assessments and analyses of weight loss, body composition changes, and blood insulin levels using obese animal models.
CT-G32/SCO-940 is a drug candidate designed to simultaneously target four hormone pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), glucagon, and amylin. Based on publicly available development data, Celltrion explained that this is the world’s first case of applying all four pathways within a single candidate molecule.
The difference from existing obesity treatments lies in the number and combination of hormone pathways involved. Novo Nordisk’s Wegovy is a single-acting GLP-1 agent that suppresses appetite and increases satiety, while Eli Lilly’s Mounjaro is a dual agonist that adds GIP, which is involved in blood glucose and energy metabolism control, to GLP-1. Eli Lilly’s retatrutide, currently in development, is a triple agonist that further includes the glucagon pathway.
Celltrion’s CT-G32/SCO-940 adds amylin to the three pathways of the triple agonist. Amylin is a hormone secreted after food intake that increases satiety and slows gastric emptying, thereby helping regulate food intake. Celltrion stated that by jointly targeting the four hormone pathways, it is developing the drug to enhance weight loss effects while reducing lean mass loss, such as muscle, that can occur during weight reduction.
The company said the preclinical study confirmed this potential differentiation. In diet-induced obese animal models, CT-G32/SCO-940 demonstrated greater weight loss compared with the triple agonist retatrutide at the same dose. It also reported that the proportion of lean mass reduction, including muscle and skeletal mass, during weight loss was relatively lower than with the comparator drug.
An effect in reducing excessively elevated blood insulin levels associated with obesity was also observed. Based on this, Celltrion stated that it has identified the potential to develop the candidate not only as an obesity treatment but also as a therapy for metabolic diseases.
However, the company noted that these results were confirmed at the animal study stage, and additional validation is required to determine whether the same effects will be seen in humans. In particular, it will be necessary to confirm through future clinical trials whether the quadruple agonist is superior in terms of weight loss efficacy and safety compared with existing dual and triple agonists.
In a pharmacokinetic evaluation conducted in primates, the drug showed sustained exposure in the body over an extended period. Based on this, Celltrion explained that it has identified the potential to develop a once-weekly dosing formulation that could improve convenience for patients.
Celltrion plans to submit an Investigational New Drug (IND) application for CT-G32/SCO-940 to the U.S. Food and Drug Administration (FDA) by February 2027. If regulatory review proceeds smoothly, the company aims to initiate global clinical development with first patient dosing targeted for the second quarter of the same year.
The company intends to develop CT-G32/SCO-940 as a new drug that can address issues such as inter-individual variability in efficacy of existing GLP-1-based therapies and muscle loss occurring during weight reduction. In parallel, it is expanding its new drug development business with antibody-drug conjugates (ADCs), multi-specific antibody anticancer agents, and autoimmune disease treatments, including candidates currently in Phase 1 clinical trials.
A Celltrion official said, “CT-G32/SCO-940 is the world’s first quadruple agonist combination simultaneously targeting GLP-1, GIP, glucagon, and amylin, and preclinical studies have confirmed its potential to differentiate from existing dual and triple agonists,” adding, “We will proceed with clinical entry without delay and develop it as a next-generation therapy that addresses not only weight loss but also improvements in body composition and metabolism.”
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News